Emerging treatment options for uterine fibroids

被引:35
|
作者
Donnez, Jacques [1 ]
Arriagada, Pablo [2 ]
Donnez, Olivier [3 ]
Dolmans, Marie-Madeleine [4 ,5 ]
机构
[1] Catholic Univ Louvain, SRI, Brussels, Belgium
[2] Gedeon Richter Preglem SA, Geneva, Switzerland
[3] Polyclin Urbain V, ELSAN Grp, Inst Sein & Chirurg Gynecol Avignon, Avignon, France
[4] Clin Univ St Luc, Gynecol Dept, Brussels, Belgium
[5] Catholic Univ Louvain, Inst Rech Expt & Clin, Pole Gynecol, Brussels, Belgium
关键词
Uterine fibroids; leiomyomas; selective progesterone receptor modulators; ulipristal acetate; surgery; medical therapy; myomectomy; infertility; PROGESTERONE-RECEPTOR MODULATORS; ULIPRISTAL ACETATE; MANAGEMENT;
D O I
10.1080/14728214.2018.1446943
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Uterine fibroids (also known as leiomyomas or myomas) are the most common form of benign uterine tumors. Current management strategies involve mainly surgical interventions, but the choice of treatment is guided by patient age and desire to preserve fertility or avoid 'radical' surgery such as hysterectomy. Areas covered: There is growing evidence of the crucial role of progesterone pathways in the pathophysiology of uterine fibroids, leading to increasing use of selective progesterone receptor modulators (SPRMs) such as ulipristal acetate. We searched all published studies on medical management of fibroids with SPRMs. Expert opinion: The need for alternatives to surgical intervention is very real, especially for women seeking to preserve their fertility. These options now exist, with SPRMs proven to treat fibroid symptoms effectively. Gynecologists now have new tools in their armamentarium, opening up novel strategies for the management of uterine fibroids.
引用
收藏
页码:17 / 23
页数:7
相关论文
共 50 条
  • [1] Current and Emerging Treatment Options for Uterine Fibroids
    Ali, Mohamed
    Ciebiera, Michal
    Wlodarczyk, Marta
    Alkhrait, Samar
    Maajid, Elise
    Yang, Qiwei
    Hsia, Shih-Min
    Al-Hendy, Ayman
    DRUGS, 2023, 83 (18) : 1649 - 1675
  • [2] Uterine fibroids: an update on current and emerging medical treatment options
    Farris, Manuela
    Bastianelli, Carlo
    Rosato, Elena
    Brosens, Ivo
    Benagiano, Giuseppe
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2019, 15 : 157 - 178
  • [3] Vilaprisan Progesterone receptor modulator Treatment of uterine fibroids
    Barra, F.
    Seca, M.
    Ferrero, S.
    DRUGS OF THE FUTURE, 2019, 44 (03) : 211 - 219
  • [4] CURRENT TREATMENT OPTIONS IN PATIENTS WITH UTERINE FIBROIDS
    Kubinova, K.
    Mara, M.
    Horak, P.
    Kuzel, D.
    AKTUALNI GYNEKOLOGIE A PORODNICTVI, 2012, 4 : 101 - 105
  • [5] Relugolix for the treatment of uterine fibroids
    Rocca, M. L.
    Palumbo, A. R.
    Lico, D.
    Fiorenza, A.
    Bitonti, G.
    D'Agostino, S.
    Gallo, C.
    Di Carlo, C.
    Zullo, F.
    Venturella, R.
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (14) : 1667 - 1674
  • [6] Emerging therapies in the medical treatment of uterine fibroids
    Goitia, Mikel
    Estadella, Josep
    MEDICINA CLINICA, 2023, 161 : S32 - S37
  • [7] Update on medical treatment of uterine fibroids
    Faustino, Fatima
    Martinho, Margarida
    Reis, Jose
    Aguas, Fernanda
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2017, 216 : 61 - 68
  • [8] Highlights on Medical Treatment of Uterine Fibroids
    Angioni, Stefano
    D'Alterio, Maurizio N.
    Daniilidis, Angelos
    CURRENT PHARMACEUTICAL DESIGN, 2021, 27 (36) : 3821 - 3832
  • [9] Emerging Treatment Options for Fibroids
    Baxter, Briana L.
    Hur, Hye-Chun
    Guido, Richard S.
    OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA, 2022, 49 (02) : 299 - 314
  • [10] Clinical Utility Of Elagolix As An Oral Treatment For Women With Uterine Fibroids: A Short Report On The Emerging Efficacy Data
    Neri, Manuela
    Melis, Gian Benedetto
    Giancane, Elena
    Vallerino, Valerio
    Pilloni, Monica
    Piras, Bruno
    Loddo, Alessandro
    Paoletti, Anna Maria
    Mais, Valerio
    INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2019, 11 : 535 - 546